Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;25(3):133-145.
doi: 10.2217/pgs-2023-0193. Epub 2024 Mar 5.

Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration

Rebekah Ryanne Wu  1   2 , Richelle Benevent  3 , Nina R Sperber  1   2   4 , Jill S Bates  2   5   6 , Daniel Villa  7 , Dilhan Weeraratne  3 , Timothy A Burrell  3 , Deepak Voora  1   2   5   8
Affiliations

Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration

Rebekah Ryanne Wu et al. Pharmacogenomics. 2024 Feb.

Abstract

Aim: Understanding barriers and facilitators to pharmacogenomics (PGx) implementation and how to structure a clinical program with the Veterans Health Administration (VA). Materials & methods: Healthcare provider (HCP) survey at 20 VA facilities assessing PGx knowledge/acceptance and qualitative interviews to understand how best to design and sustain a national program. Results: 186 (12% response rate) surveyed believed PGx informs drug efficacy (74.7%) and adverse events (71.0%). Low confidence in knowledge (43.0%) and ability to implement (35.4-43.5%). 23 (60.5% response rate) interviewees supported a nationally program to oversee VA education, consultation and IT resources. Prescribing HCPs should be directing local activities. Conclusion: HCPs recognize PGx value but are not prepared to implement. Healthcare systems should build system-wide programs for implementation education and support.

Keywords: education; healthcare systems; implementation science; pharmacogenomics; quality improvement.

PubMed Disclaimer

Conflict of interest statement

Competing interests disclosure

RRW is employed by 23andMe. She is a co-founder and shareholder of MeTree&You. Neither organization supported her effort, contributed, or benefited in any way from the research contained in this manuscript. The remaining authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.. Interviewees invited and who participated by specialty area.
See this image and copyright information in PMC

References

    1. Ross S, Krebs K, Pare G, Milani L. Pharmacogenomics in stroke and cardiovascular disease: state of the art. Stroke 54(1), 270–278 (2023). - PubMed
    1. Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in cytotoxic chemotherapy of cancer. Methods Mol. Biol. 2547, 63–94 (2022). - PubMed
    1. Scudeler MM, Manochio C, Braga Pinto AJ, Santos Cirino HD, da Silva CS, Rodrigues-Soares F. Breast cancer pharmacogenetics: a systematic review. Pharmacogenomics 24(2), 107–122 (2023). - PubMed
    1. Oslin DW, Lynch KG, Shih MC et al. Effect of pharmacogenomic testing for drug–gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial. JAMA 328(2), 151–161 (2022). - PMC - PubMed
    1. Swen JJ, van der Wouden CH, Manson LE et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 401(10374), 347–356 (2023). - PubMed

LinkOut - more resources